Scottish Biotech Biotangents Secures £2.3M Investment to Revolutionize Dairy Farming with Breakthrough Diagnostic Device

Scottish biotech company Biotangents has secured a £2.3 million investment to develop and launch a revolutionary on-farm, point-of-care diagnostic device aimed at addressing disease in dairy cows. The company's technology, designed to combat bovine mastitis, is set to significantly impact the global dairy farming industry, which faces an estimated £20 billion annual cost due to this disease.

Biotangents' innovative solution offers highly accurate results in less than two hours, enabling farmers to make informed treatment decisions and potentially reduce unnecessary antibiotic usage by up to 40 percent. The investment round was led by St Andrews-based investment firm Eos and British Business Investments through their Regional Angels Programme, with participation from existing investors Kelvin Capital and Scottish Enterprise. Following the investment, Biotangents plans to conduct on-farm trials across the UK and internationally. The company also foresees future applications for its technology in human healthcare and environmental monitoring.